We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+44.05%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$107M
AUM Growth
-$43.3M
Cap. Flow
-$29M
Cap. Flow %
-27.1%
Top 10 Hldgs %
87.68%
Holding
30
New
3
Increased
4
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$2.32M
2
MYGN icon
Myriad Genetics
MYGN
+$1.32M
3
CAVA icon
CAVA Group
CAVA
+$77.2K
4
FORA
Forian
FORA
+$814

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.93M
2
BHVN icon
Biohaven
BHVN
+$4.13M
3
ARDX icon
Ardelyx
ARDX
+$3.88M
4
EYPT icon
EyePoint Inc
EYPT
+$3.21M
5
PACB icon
Pacific Biosciences
PACB
+$1.88M

Sector Composition

Rank Sector Weight
1 Healthcare 85.34%
2 Consumer Discretionary 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$2.01B
$28.9M 26.97%
1,105,768
-20,839
-2% -$395K
BHVN icon
2
Biohaven
BHVN
$2.01B
$24.3M 22.68%
700,450
-104,400
-13% -$4.13M
ARDX icon
3
Ardelyx
ARDX
$1.23B
$11M 10.29%
1,488,131
-551,569
-27% -$3.88M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$8.78M 8.2%
233,200
-188,383
-45% -$7.93M
BHVN icon
5
CALL
Biohaven
BHVN
$2.01B
$3.99M 3.72%
115,000
-4,500
-4% -$178K
QDEL icon
6
QuidelOrtho
QDEL
$1.21B
$3.93M 3.67%
118,291
-38,910
-25% -$1.59M
EYPT icon
7
CALL
EyePoint Inc
EYPT
$1.04B
$3.81M 3.56%
438,100
+409,500
+1,432% +$5.72M
FORA
8
DELISTED
Forian
FORA
$3.59M 3.35%
1,356,107
+300
+0% +$814
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.24B
$3.31M 3.09%
535,558
– –
PHAT icon
10
Phathom Pharmaceuticals
PHAT
$726M
$2.32M 2.16%
+225,000
New +$2.32M
EYPT icon
11
EyePoint Inc
EYPT
$1.04B
$2.02M 1.88%
231,857
-230,000
-50% -$3.21M
ARDX icon
12
CALL
Ardelyx
ARDX
$1.23B
$1.92M 1.79%
259,600
-11,300
-4% -$79.5K
MYGN icon
13
CALL
Myriad Genetics
MYGN
$289M
$1.82M 1.7%
+74,500
New +$1.63M
PLTR icon
14
CALL
Palantir
PLTR
$301B
$1.77M 1.65%
70,000
+45,000
+180% +$1.01M
CAVA icon
15
CAVA Group
CAVA
$7.51B
$1.73M 1.61%
18,600
+1,000
+6% +$77.2K
MYGN icon
16
Myriad Genetics
MYGN
$289M
$1.47M 1.37%
+60,000
New +$1.32M
SWTX
17
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$671K 0.63%
17,800
-25,100
-59% -$1.06M
PACB icon
18
Pacific Biosciences
PACB
$441M
$580K 0.54%
423,138
-932,888
-69% -$1.88M
BIIB icon
19
Biogen
BIIB
$29.8B
$559K 0.52%
2,412
– –
WBA
20
DELISTED
Walgreens Boots Alliance
WBA
$333K 0.31%
27,500
– –
AGEN
21
Agenus
AGEN
$326M
$293K 0.27%
17,500
-35,848
-67% -$433K
BDSX icon
22
Biodesix
BDSX
$228M
$44.2K 0.04%
1,446
-72
-5% -$2.06K
AXDX
23
DELISTED
Accelerate Diagnostics
AXDX
– –
-42,101
Closed -$41.7K
IMMP
24
Immutep
IMMP
$56.1M
– –
-564,879
Closed -$1.32M
OPTN
25
DELISTED
OptiNose
OPTN
– –
-21,667
Closed -$475K
1
2

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q2 2024 Portfolio in Review

As of Q2 2024, Oracle Investment Management held 30 positions worth $107M, down 29% from $150M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Oracle Investment Management withdrew a net $29M in Q2 2024, closing 8 positions and reducing 12 holdings. Its most notable exit was Immutep, an estimated $1.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Oracle Investment Management opened a new position in Phathom Pharmaceuticals worth $2.32M.

  • Oracle Investment Management's largest Q2 2024 buy was Phathom Pharmaceuticals: 225,000 shares worth $2.32M.
  • Oracle Investment Management added most to CAVA Group in Q2 2024, an estimated $77.2K increase.
  • Oracle Investment Management's biggest Q2 2024 reduction was SpringWorks Therapeutics, cutting an estimated $7.93M.
  • Oracle Investment Management fully exited Immutep in Q2 2024, selling an estimated $1.32M.
  • Oracle Investment Management's ten largest holdings make up 88% of its $107M portfolio in Q2 2024.
  • Oracle Investment Management opened 3 new positions and closed 8 in Q2 2024.
  • Oracle Investment Management's portfolio value fell 29% quarter-over-quarter to $107M.

Based on Oracle Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.